Yves, Henrotin
Herman, Julie
Uebelhoer, Melanie
Wauquier, Fabien
Boutin-Wittrant, Line
Donneau, Anne-Françoise
Monseur, Justine
Fotso, Variance Mokam
Duquenne, Marie
Wagner, Mélanie
Bouvret, Elodie
Costes, Bérénice
Wittrant, Yohann
Article History
Received: 10 February 2023
Accepted: 16 August 2023
First Online: 21 September 2023
Declarations
:
: Both clinical studies were conducted in accordance with the Declaration of Helsinki. Study #1 was approved by the Ethics Committee of the University Hospital of Liège in Belgium (Comité d’Ethique Hospitalo-Facultaire Universitaire de Liège) (protocol code B707202042984 on April 17th, 2020). The study was registered on clinicaltrials.gov with the identifier NCT04420091 on 09/06/2020. Study #2 was approved by the French Ethical Committee (2021-ND77 RIPH2 HPS / N° SI RIPH: 21.01436.000014 / N° EudraCT/ID RCB: 2021-A01773-38 / Comité de Protection des Personnes CPP Paris, Ile-de-France 1; approved 08 October 2021). Written informed consent to participate in the study was obtained from all subjects before enrolment.
: Not applicable.
: YH is the founder and president of Artialis SA, a spin-off company of the University of Liège. YH has also received consulting and speaker fees from Tilman SA, Nestlé, Laboratoire Expanscience, Heel, Megalab, Genequine, LABHRA, and Biose. JH, MU, VMF and BC are employees of Artialis SA. EB is an employee of Abyss Ingredients. F.W. and L.W.-B. work for Clinic’n’Cell SAS (Faculty of Medicine and Pharmacy Clermont-Ferrand- France); Y.W. provides scientific consulting for Clinic’n’Cell SAS. M.W., A.F.D. and J.M. have no competing interests.